Xeron Clinical Laboratories INC.

Xeron Clinical Laboratories INC. was paid $14.12M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is 82306, Vitamin D; 25 hydroxy, includes fraction(s), if performed — 9.1% of everything it billed.

33Billing provider infoXERON CLINICAL LABORATORIES INC.
KENILWORTH, NJ 07033

33aNPI1336361575assigned 05/03/2007

33bProvider typeClinical Medical Laboratory

28Total paid$14.12M

24GClaims1,806,773

24DCodes billed228

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#22 of 122

Median peer was paid$1.29M

This provider vs. median11×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	317,640	$2.51M
2019	378,889	$2.85M
2020	241,459	$1.76M
2021	190,110	$1.92M
2022	204,199	$2.08M
2023	155,231	$1.20M
2024incomplete	319,245	$1.80M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	9.1%	61,840	61,429	$1.28M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.1%	85,234	53,779	$858K
80050	General health panel	5.8%	39,093	38,360	$815K
86481		5.5%	22,466	22,330	$777K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	5.4%	14,304	13,193	$761K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	4.2%	36,889	36,279	$598K
80061	Lipid panel	3.7%	116,706	116,178	$521K
83036	Hemoglobin; glycosylated (A1C)	3.7%	86,910	86,531	$516K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	3.3%	32,630	32,362	$471K
80053	Comprehensive metabolic panel	3.0%	83,029	82,264	$428K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.9%	21,116	12,666	$408K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	2.7%	5,935	3,945	$376K

216 more codes

86480		2.7%	11,110	$374K
84443	Thyroid stimulating hormone (TSH)	2.1%	55,139	$297K
82607		1.9%	32,838	$270K
86769		1.8%	8,443	$254K
84439		1.8%	46,686	$252K
83655		1.7%	28,633	$233K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.7%	109,094	$233K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.6%	12,866	$220K
82746		1.4%	24,848	$202K
86328		1.4%	7,837	$198K
86703		1.3%	18,604	$179K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.2%	16,068	$168K
86803		<1%	19,955	$130K
81001		<1%	60,916	$127K
87340		<1%	18,545	$123K
84153		<1%	8,916	$115K
86706		<1%	17,440	$111K
82728		<1%	12,492	$106K
84480		<1%	21,588	$93K
86762		<1%	8,865	$87K
86765		<1%	9,113	$79K
82043		<1%	23,047	$76K
80074		<1%	4,724	$74K
86592		<1%	33,365	$72K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	643	$65K
86704		<1%	9,564	$62K
80048	Basic metabolic panel (calcium, ionized)	<1%	13,187	$60K
86708		<1%	9,262	$59K
80076		<1%	14,603	$56K
83992		<1%	9,524	$55K
84403		<1%	3,148	$54K
87086	Culture, bacterial; quantitative colony count, urine	<1%	10,685	$53K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	1,336	$50K
86735		<1%	8,351	$48K
81003		<1%	34,021	$43K
86780		<1%	5,461	$43K
86787		<1%	7,198	$41K
84154		<1%	2,930	$40K
85660		<1%	14,186	$34K
82652		<1%	2,069	$33K
83001		<1%	2,551	$33K
83540		<1%	10,939	$32K
83002		<1%	2,534	$31K
84550		<1%	10,894	$31K
84481		<1%	4,391	$28K
83550		<1%	8,795	$28K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	3,056	$27K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	1,464	$27K
80348		<1%	10,913	$26K
80354		<1%	11,094	$26K
87070		<1%	4,993	$25K
80323		<1%	7,331	$24K
83525		<1%	3,197	$24K
82670		<1%	1,240	$24K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	1,123	$24K
84270		<1%	2,498	$23K
80375		<1%	7,470	$22K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,642	$21K
84702		<1%	2,829	$21K
80349		<1%	9,895	$20K
80364		<1%	8,442	$20K
80373		<1%	9,019	$20K
86696		<1%	2,076	$19K
85045		<1%	9,240	$19K
83735		<1%	5,834	$19K
83021		<1%	1,474	$19K
82274		<1%	5,703	$18K
80372		<1%	8,455	$17K
85027		<1%	9,083	$17K
80358		<1%	9,136	$17K
82465		<1%	6,113	$17K
80324		<1%	6,233	$17K
87631		<1%	558	$16K
86317		<1%	3,306	$16K
80359		<1%	9,051	$16K
80361		<1%	8,285	$16K
80353		<1%	9,377	$16K
80371		<1%	6,442	$16K
80347		<1%	7,219	$15K
80356		<1%	7,897	$15K
87088		<1%	2,377	$15K
86038		<1%	3,843	$15K
80365		<1%	7,996	$15K
80367		<1%	8,112	$14K
82627		<1%	956	$14K
88142		<1%	966	$14K
84402		<1%	904	$14K
84146		<1%	1,035	$14K
84436		<1%	5,539	$13K
80350		<1%	6,869	$13K
80338		<1%	6,440	$13K
80357		<1%	8,225	$13K
86003		<1%	510	$12K
80337		<1%	5,406	$12K
80325		<1%	3,510	$11K
80370		<1%	5,156	$11K
86376		<1%	1,111	$10K
86800		<1%	1,198	$10K
86695		<1%	1,707	$10K
85651		<1%	6,943	$10K
80355		<1%	6,003	$10K
87184		<1%	2,176	$10K
85610		<1%	3,905	$9K
86431		<1%	2,934	$9K
87077		<1%	1,607	$9K
80345		<1%	5,894	$9K
86140		<1%	3,788	$9K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,918	$9K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	710	$9K
85730		<1%	2,570	$8K
86200		<1%	2,270	$8K
80334		<1%	4,141	$7K
80344		<1%	4,716	$7K
86705		<1%	1,351	$7K
84460		<1%	2,014	$7K
80340		<1%	3,947	$6K
83970		<1%	214	$6K
80366		<1%	4,876	$6K
86618		<1%	340	$6K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,120	$6K
86141		<1%	757	$6K
84100		<1%	1,873	$6K
80171		<1%	905	$5K
80183		<1%	926	$5K
80186		<1%	926	$5K
80175		<1%	920	$5K
85044		<1%	3,516	$5K
80362		<1%	2,418	$5K
87071		<1%	1,465	$5K
82570		<1%	2,588	$5K
80321		<1%	1,049	$5K
87517		<1%	192	$5K
86901		<1%	1,914	$5K
80368		<1%	2,939	$4K
36415	Collection of venous blood by venipuncture	<1%	5,844	$4K
82977		<1%	1,456	$4K
86900		<1%	1,616	$4K
86677		<1%	584	$4K
82105		<1%	837	$4K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	103	$3K
88120		<1%	27	$3K
82947		<1%	1,500	$3K
87186		<1%	596	$3K
84450		<1%	813	$3K
82150		<1%	784	$3K
82785		<1%	312	$2K
80342		<1%	1,057	$2K
80346		<1%	786	$2K
83690		<1%	649	$2K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	616	$2K
82550		<1%	679	$2K
86709		<1%	615	$2K
81513		<1%	123	$2K
82533		<1%	180	$2K
84703		<1%	899	$2K
87634		<1%	114	$2K
82040		<1%	901	$2K
83090		<1%	136	$2K
86060		<1%	451	$2K
87081		<1%	508	$2K
87581		<1%	481	$2K
87486		<1%	481	$2K
83615		<1%	648	$2K
80069		<1%	222	$1K
82248		<1%	516	$1K
81025		<1%	630	$1K
80369		<1%	602	$1K
85014		<1%	941	$1K
87481		<1%	63	$1K
85018		<1%	894	$1K
80201		<1%	1,001	$1K
84479		<1%	1,336	$1K
80360		<1%	1,187	$1K
82565		<1%	597	$999.17
80333		<1%	1,003	$993.27
87808		<1%	382	$971.86
87536		<1%	15	$963.34
84144		<1%	137	$859.08
87521	Neg quan hep c or qual rna	<1%	36	$798.29
87116		<1%	145	$780.11
87045		<1%	158	$776.47
82378		<1%	64	$769.02
80339		<1%	897	$464.21
87206		<1%	145	$390.25
83721		<1%	223	$338.39
80051		<1%	104	$333.68
83718		<1%	95	$333.10
86304		<1%	27	$331.88
84132		<1%	135	$274.56
87015		<1%	145	$266.07
83986		<1%	1,218	$256.62
84478		<1%	92	$255.04
80377		<1%	825	$222.90
84311		<1%	1,117	$219.11
82542		<1%	289	$172.20
84075		<1%	66	$167.88
82247		<1%	121	$164.32
82270		<1%	75	$157.33
86593		<1%	67	$156.64
83020		<1%	14	$118.65
87338		<1%	28	$115.21
87350		<1%	13	$103.29
80343		<1%	100	$97.63
80164		<1%	34	$94.84
86790		<1%	25	$93.86
84520		<1%	135	$82.91
84155		<1%	90	$52.25
85652		<1%	43	$42.20
84156		<1%	13	$37.90
85007		<1%	33	$28.52
80363		<1%	66	$19.81
82310		<1%	29	$7.43
82374		<1%	374	$4.39
84295		<1%	29	$4.33
82435		<1%	29	$4.14
99080		0%	3,423	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFISCH, CHAYA (OWNER)